Director/PDMR Shareholding

RNS Number : 1090G

AstraZeneca PLC

24 May 2017

 

24 May 2017 15:00 BST

TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES

Disclosure under Article 19 of the EU Market Abuse Regulation

AstraZeneca PLC (the Company) announces that, on 23 May 2017, it was notified by Mark Mallon, a Person Discharging Managerial Responsibilities of the Company, that, on 23 May 2017, Mr Mallon sold 20,000 American Depositary Shares (ADSs). Two ADSs are equivalent to one ordinary share of $0.25 in the Company.

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Mark Mallon
2	Reason for the notification
a)	Position/status	Person Discharging Managerial Responsibilities
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	AstraZeneca PLC American Depositary Shares CUSIP: 046353108
b)	Nature of the transaction	Sale of AstraZeneca PLC American Depositary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) US$ 33.900214 20,000
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction
e)	Date of the transaction	23 May 2017
f)	Place of the transaction	NYSE

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Enquiries
Esra Erkal-Paler	UK/Global	[phone]
Karen Birmingham	UK/Global	[phone]
Rob Skelding	UK/Global	[phone]
Jacob Lund	Sweden	[phone]
Michele Meixell	US	[phone]
Investor Relations
Thomas Kudsk Larsen		[phone]
Craig Marks	Finance, Fixed Income, M&A	[phone]
Henry Wheeler	Oncology	[phone]
Mitchell Chan	Oncology	[phone]
Lindsey Trickett	Cardiovascular & Metabolic Diseases	[phone]
Nick Stone	Respiratory	[phone]
Christer Gruvris	Autoimmunity, Neuroscience & Infection	[phone]
US toll free		[phone]

Adrian Kemp

Company Secretary, AstraZeneca PLC

 

END

 

 

DSHUSARRBVAVUAR